249
Participants
Start Date
July 31, 2012
Primary Completion Date
May 31, 2014
Study Completion Date
May 31, 2014
Rotigotine
"Transdermal Patch~Content:~2 mg /24 h (10 cm\^2), 4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2)~For early-stage Parkinson's disease, receive Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 24 week maintenance period"
Placebo Patch
"Transdermal Patch~Size:~10 cm\^2, 20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo will receive matching placebo patches"
001, Beijing
002, Beijing
019, Beijing
025, Beijing
017, Changchun
007, Chengdu
027, Chengdu
021, Fuzhou
010, Guangzhou
011, Guangzhou
014, Guangzhou
015, Guangzhou
005, Hangzhou
013, Hangzhou
018, Hangzhou
023, Jinan
003, Shanghai
004, Shanghai
009, Shanghai
008, Suzhou
016, Tianjin
006, Wuhan
022, Wuhan
024, Wuhan
Lead Sponsor
UCB Pharma
INDUSTRY